Evaluation of serum autoantibody levels in the diagnosis of ovarian endometrioma

Yi YC, Yu‐Chiao Yi, Yu-Chiao Yi, Shih-Chi Wang, Shih‐Chi Wang, Wang SC, Chun‐Chin Chao, Chun-Chin Chao, Chao CC, Chia‐Ling Su, Chia-Ling Su, Su CL, Lee YL, Yao-Ling Lee, Yao‐Ling Lee, Chen LY, Lingyun Chen, Ling-Yun Chen
Journal of clinical laboratory analysis · 2010 · vol. 24(5) , pp. 357–362 · doi:10.1002/jcla.20415 · PMID:20872572 · PMC6647576 · W1997544588
Diagnostic accuracy OA: bronze CC0 ⤵ 10 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

Serum IMP1 autoantibodies alone or combined with cyclin B1 autoantibodies showed potential diagnostic accuracy for ovarian endometrioma in this study.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: We analyzed autoantibodies against tumor-associated antigens (TAAs) in the serum of patients with endometrioma and healthy controls to determine whether autoantibodies can be accurate biomarkers for the diagnosis of ovarian endometrioma. METHODS: Serum samples were obtained from 56 patients with endometriosis and 66 healthy women who served as normal controls. The titers of antibodies against a panel of eight TAAs were analyzed using enzyme-linked immunosorbent assay. RESULTS: We found that the serum IGFII mRNA-binding protein 1 (IMP1) autoantibody and cyclin B1 autoantibody could discriminate between healthy controls and endometriosis patients (AUC-ROC 0.777; 95% confidence interval [CI] 0.694-0.860, P<0.0005, and AUC-ROC 0.614; 95%confidence interval [CI] 0.513-0.714, P=0.031, respectively). Using 0.073 and 0.007 as the cutoff values for IMP1 and Cyclin B1 autoantibody, respectively, the sensitivity and specificity of IMP1 were 85.7 and 63.6%, respectively. When cylcin B1 was combined with IMP1, the specificity increased to 72.7% and the sensitivity slightly decreased to 83.9%. CONCLUSIONS: Our data suggest that IMP1 alone or combined with cyclin B1 seems to fulfill the requirements of sensitivity and specificity to become a useful clinical biomarker of endometrioma. However, further studies will be required to establish the predictive value and to support the clinical use of IMP1/cyclin B1 in the diagnosis and/or screening of endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosisendometrioma

MeSH descriptors

Autoantibodies Biomarkers, Tumor Cyclin B1 Endometriosis Ovarian Neoplasms RNA-Binding Proteins Adolescent Adolescent Adult Adult Autoantibodies Autoantibodies Biomarkers, Tumor Biomarkers, Tumor Case-Control Studies Case-Control Studies Cyclin B1 Cyclin B1 Endometriosis Endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (31)

Cited by (10)

Source provenance

europepmc
last seen: 2026-11-04T06:09:08.831786+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:08:04.945943+00:00
License: CC0 · commercial use OK